PERSON – Page 30

Frazier Replenishes Fund with $630 Million for Public Biotech Investments

7 months ago talkbio0Tagged biotech fund, Biotechnology, Frazier, Investments, public biotechs

Frazier, biotech fund, public biotechs, investment, biotechnology

Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights

7 months ago talkbio0Tagged apalutamide, Comparative Efficacy, enzalutamide, Erleada, Malignant neoplasm of prostate, nmCRPC, non-metastatic castration-resistant prostate cancer, profiles, Real-World Study, Safety

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles

GE HealthCare’s Flyrcado (flurpiridaz F 18) PET Radiotracer Receives FDA Approval for Enhanced Detection of Coronary Artery Disease

7 months ago talkbio0Tagged Approved, Cardiac imaging, Coronary Arteriosclerosis, F 18, Flyrcado, Health care facility, nuclear cardiology, Pet Animal, Radiotracers, United States Food and Drug Administration

GE HealthCare, Flyrcado, flurpiridaz F 18, PET radiotracer, Coronary artery disease (CAD), FDA approval, Cardiac imaging, Nuclear cardiology

Kailera Secures $400M Funding to Advance China-Developed Obesity and Diabetes Therapies

7 months ago talkbio0Tagged Diabetes, Kailera, Obesity

Kailera, obesity, diabetes, China-developed drugs, $400M funding, pharmaceuticals, biotech

Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera

7 months ago talkbio0Tagged Amneal, Leadership, Manufacture, Metsera, Obesity, Partnership, strategic collaboration, Transition Mutation

Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition

FDA Tracker: Fresenius Kabi and Formycon’s Stelara Biosimilar Set for 2025 Launch

7 months ago talkbio0Tagged Approved, biosimilar competition, Formycon, Fresenius, J&J, settlements, Stelara biosimilar, United States Food and Drug Administration, ustekinumab

Stelara biosimilar, Fresenius Kabi, Formycon, FDA approval, ustekinumab, Johnson & Johnson, J&J settlements, biosimilar competition

Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy

7 months ago talkbio0Tagged Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, New, psychiatric medication, Schizophrenia, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication

Masimo Appoints Michelle Brennan as Interim CEO Following Joe Kiani’s Resignation

7 months ago talkbio0Tagged board of directors, Brennan, Capital Management, CEO, Kiani, Masimo, Michelle, Politan, resignation

Masimo, Joe Kiani, Michelle Brennan, Politan Capital Management, Interim CEO, Board of Directors, Resignation

UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases

7 months ago talkbio0Tagged Ankylosing spondylitis, approvals, Arthritis, Psoriatic, Bimzelx, IL17A protein, human, IL17F gene, Inhibitor, non-radiographic axial, Spondylarthritis, UCB, United States Food and Drug Administration

Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor

UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Systemic Lupus Erythematosus, Plan Second Phase 3 Trial

7 months ago talkbio0Tagged Biogen, dapirolizumab, Diptera, Lupus Erythematosus, Systemic, pegol, Phase 3 trial, PHOENYCS, PHOENYCS GO, UCB

UCB, Biogen, Dapirolizumab Pegol, Systemic Lupus Erythematosus, Phase 3 Trial, PHOENYCS GO, PHOENYCS FLY